GARD: A move toward precision radiotherapy

Despite important technological innovations to allow more accurate and precise targeting for external-beam radiotherapy, such as intensity modulated radiotherapy (IMRT), and better consideration of patient and tumour characteristics, radiation oncology still has not yet developed tools analogous to HER2/neu testing to identify breast tumours that might respond to the targeted agent trastuzumab (Herceptin). But that might be changing.
Oncology Nurse Advisor